Search - tctmd.com

Displaying 381 - 400 of 400

Sort: Relevancy | Date

Presentation TCT 2013

Cost-effectiveness Of Transcatheter Left Atrial Appendage Occlusion Compared With 5 Alternative Anticoagulation Strategies For Stroke Prevention In Atrial Fibrillation: A Markov...

Presenter: Bryan Yan, Chow Innes, Yat Yin Lam, Vivian Lee, Cheuk Man Yu

January 31, 2013

Presentation TCT 2012

Will Transcatheter Left Atrial Appendage Closure Transform Management of Atrial Fibrillation?

Presenter: Vivek Reddy

October 25, 2012

Presentation TCT 2012

Novel Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation

Presenter: Jonathan Halperin

October 25, 2012

Presentation TCT 2012

4q25 and Prediction of Atrial Fibrillation: How Can This Information Help the Clinician?

Presenter: Paddy Barrett

October 25, 2012

Presentation TCT 2012

Strategies for the ACS Patient with Chronic Atrial Fibrillation

Presenter: C. Michael Gibson

October 24, 2012

Presentation TCT 2012

Lone Surgical Treatment of Atrial Fibrillation: Meaningful Progress in the Past 15 Years?

Presenter: William Cohn

October 24, 2012

Presentation TCT 2012

Does Atrial Fibrillation Ablation Reduce Cardioembolic Stroke?

Presenter: Vivek Reddy

October 24, 2012

Presentation TCT 2012

Case 4: The Patient with Atrial Fibrillation Presenting with an Acute Coronary Syndrome

Presenter: Michael Ezekowitz

October 24, 2012

Presentation TCT 2012

Anticoagulation Choices for Atrial Fibrillation: Which Drug for Which Patient?

Presenter: Michael Ezekowitz

October 24, 2012

Presentation TCT 2012

TCT-84. Watchman Left Atrial Appendage Closure in Atrial Fibrillation Patients 75 Years or Greater; A Sub-Analysis of the PROTECT AF Study

Presenter: Saibal Kar

October 23, 2012

Presentation TCT 2012

TCT-83. Watchman Left Atrial Appendage Closure in Atrial Fibrillation Patients with Contraindication to Oral Anticoagulation: the “Aspirin Plavix Registry” (ASAP)

Presenter: Horst Sievert

October 23, 2012

Presentation TCT 2012

TCT-62. Impact of Atrial Fibrillation in Patients with STEMI Before and After Primary PCI: Insights from the HORIZONS-AMI Trial

Presenter: A. Rene

October 23, 2012

Presentation TCT 2012

Modeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores?

Presenter: Roxana Mehran

October 23, 2012

Presentation TCT 2012

Atrial Fibrillation:
1. CHADS2 vs. CHA2DS2-VASc Risk Assessment.
2. AHA/ACC vs. ACCP/ESC Approach to Stroke Prevention.

Presenter: Peter Brady

October 23, 2012

Presentation TCT 2012

New-Onset Atrial Fibrillation After TAVR: More Frequent than Reported and a Possible Predictor of Stroke

Presenter: Josep Rodes-Cabau

October 22, 2012

Presentation TVT 2012

The Evolving Standard of Care: Oral Antithrombotic Agents for Stroke Prevention in Atrial Fibrillation

Presenter: Gregg Stone

June 05, 2012

Presentation TVT 2012

The Evolving Standard of Care: Atrial Fibrillation Ablation

Presenter: Shephal Doshi

June 05, 2012

Presentation

Cost-effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: S. Lee

June 05, 2012

Presentation

Outcomes of Discontinuing Rivaroxaban vs. Warfarin in Patients with Nonvalvular Atrial Fibrillation (A-fib)

Presenter: M. Patel

April 25, 2012

Presentation TCT 2012

The New 320-Row Computed Tomography With Lower Radiation Exposure to Rule-out Coronary Artery Disease in Patients with Atrial Fibrillation

Presenter: Francesco Pelliccia, Antonietta Evangelista, Amedeo Pergolini, Vincenzo Pasceri, Nicola Viceconte, Giuseppe Pannarale, Salvatore Varrica, Susanna Romitelli, Massimo Pellegrini, Carlo Gaudio

January 03, 2012

Advertisement

Cost-effectiveness Of Transcatheter Left Atrial Appendage Occlusion Compared With 5 Alternative Anticoagulation Strategies For Stroke Prevention In Atrial Fibrillation: A Markov...

Will Transcatheter Left Atrial Appendage Closure Transform Management of Atrial Fibrillation?

Novel Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation

4q25 and Prediction of Atrial Fibrillation: How Can This Information Help the Clinician?

Strategies for the ACS Patient with Chronic Atrial Fibrillation

Lone Surgical Treatment of Atrial Fibrillation: Meaningful Progress in the Past 15 Years?

Does Atrial Fibrillation Ablation Reduce Cardioembolic Stroke?

Case 4: The Patient with Atrial Fibrillation Presenting with an Acute Coronary Syndrome

Anticoagulation Choices for Atrial Fibrillation: Which Drug for Which Patient?

TCT-84. Watchman Left Atrial Appendage Closure in Atrial Fibrillation Patients 75 Years or Greater; A Sub-Analysis of the PROTECT AF Study

TCT-83. Watchman Left Atrial Appendage Closure in Atrial Fibrillation Patients with Contraindication to Oral Anticoagulation: the “Aspirin Plavix Registry” (ASAP)

TCT-62. Impact of Atrial Fibrillation in Patients with STEMI Before and After Primary PCI: Insights from the HORIZONS-AMI Trial

Modeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores?

Atrial Fibrillation:
1. CHADS2 vs. CHA2DS2-VASc Risk Assessment.
2. AHA/ACC vs. ACCP/ESC Approach to Stroke Prevention.

New-Onset Atrial Fibrillation After TAVR: More Frequent than Reported and a Possible Predictor of Stroke

The Evolving Standard of Care: Oral Antithrombotic Agents for Stroke Prevention in Atrial Fibrillation

The Evolving Standard of Care: Atrial Fibrillation Ablation

Cost-effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

Outcomes of Discontinuing Rivaroxaban vs. Warfarin in Patients with Nonvalvular Atrial Fibrillation (A-fib)

The New 320-Row Computed Tomography With Lower Radiation Exposure to Rule-out Coronary Artery Disease in Patients with Atrial Fibrillation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content